Literature DB >> 16036437

Serum levels of soluble intercellular adhesion molecule-1 (s-ICAM-1) and soluble endothelial leukocyte adhesion molecule-1(s-ELAM-1) in amyotrophic lateral sclerosis.

M Rentzos1, M Michalopoulou, C Nikolaou, A Rombos, A Dimitrakopoulos.   

Abstract

Immunological disturbances have been implicated in the pathogenesis of amyotrophic lateral sclerosis (ALS). Adhesion molecules are markers of activated endothelial cells up-regulated by action of cytokines. To investigate the activation or inactivation of the vascular cells in ALS, serum soluble intercellular adhesion molecule-1 (s-ICAM-1) and soluble E-selectin (s-ELAM-1) were evaluated (ELISA) in 16 patients with ALS, 30 patients with non-inflammatory neurological diseases (NINDS) and 15 healthy control subjects. Patients with ALS had no higher s-ICAM-1 levels compared with the NINDS patients and the control subjects (p<0.31 and p<0.21, respectively). s-ELAM levels were not statistically significant compared with the NINDS patients and healthy subjects (p<0.21 and p<0.24, respectively). We conclude that the low values of s-ICAM-1 and s-ELAM-1 in the serum of ALS patients do not exclude the presence of immunological abnormality in this disorder. Soluble E-selectin is a glycoprotein which is considered an exclusive marker of endothelial activation. Its low level in our study may suggest a neural rather than an endothelial s-ICAM origin in patients with ALS.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16036437     DOI: 10.1080/14660820410021311

Source DB:  PubMed          Journal:  Amyotroph Lateral Scler Other Motor Neuron Disord        ISSN: 1466-0822


  3 in total

1.  Increased peripheral blood inflammatory cytokine levels in amyotrophic lateral sclerosis: a meta-analysis study.

Authors:  Yang Hu; Chang Cao; Xiao-Yan Qin; Yun Yu; Jing Yuan; Yu Zhao; Yong Cheng
Journal:  Sci Rep       Date:  2017-08-22       Impact factor: 4.379

2.  Combination of serum and CSF neurofilament-light and neuroinflammatory biomarkers to evaluate ALS.

Authors:  Alexandre Brodovitch; José Boucraut; Emilien Delmont; Amandine Parlanti; Aude-Marie Grapperon; Shahram Attarian; Annie Verschueren
Journal:  Sci Rep       Date:  2021-01-12       Impact factor: 4.379

Review 3.  Immune Modulation in the Treatment of Amyotrophic Lateral Sclerosis: A Review of Clinical Trials.

Authors:  Syed I Khalid; Leonel Ampie; Ryan Kelly; Shafeeq S Ladha; Christopher Dardis
Journal:  Front Neurol       Date:  2017-09-25       Impact factor: 4.003

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.